Shots:

• CytoReason to receive a $20M equity investment while Pfizer gets the right to use CytoReason’s AI technology for drug development programs & options to license CytoReason’s platform & disease models
• Pfizer will be responsible to fund supplementary project support with a deal value of ~$110M over the 5yrs. & also gets multiple insights into R&D programs across ~20 diseases by using AI technology & has used biological models in its research for the immune system
• The research agreement and financing will allow using machine learning AI to develop high-resolution models in new therapeutic areas & develop novel treatments for immunological-mediated and immuno-oncology disorders

Ref: Pfizer | Image: Pfizer